RxDoctor Payments Data

Christopher Denapoles, MD

Family Medicine · Pensacola, FLNPI 1578973715

Payments from drug & device makers

$588in general payments, 2019–2025

Across 23 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$207
  • Novo Nordisk$99
  • Boehringer Ingelheim$61
  • Otsuka America Pharmaceutical, Inc.$47
  • Alpha Cognition USA, Inc.$46
  • Lilly USA, LLC$30
  • plus $99 from 6 others

What the payments were for

  • Food & beverage$50386%
  • Education$8514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$588 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$32,625
Medicare patients
192
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,045$302,376
TrulicityDulaglutide375$127,675
Invega SustennaPaliperidone Palmitate24$79,715
XareltoRivaroxaban197$55,270
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$54,814
IngrezzaValbenazine Tosylate14$52,018
EntrestoSacubitril/Valsartan112$31,824
LinzessLinaclotide56$31,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$30,234
Atorvastatin Calcium1,585$29,444
Breo ElliptaFluticasone/Vilanterol66$27,147
JardianceEmpagliflozin72$21,586
MyrbetriqMirabegron91$21,563
SantylCollagenase Clostridium Hist.63$20,700
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog141$19,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$17$134,985221 claims
Lilly USA, LLCTrulicity$30$127,675375 claims
Neurocrine Biosciences, Inc.Ingrezza$19$52,01814 claims
Boehringer IngelheimJardiance$61$21,58672 claims
AstraZenecaLokelma, Breztri Aerosphere$207$15,33841 claims
MerckJanuvia$15$7,92028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →